GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (SSE:4502) » Definitions » Capex-to-Revenue

Takeda Pharmaceutical Co (SSE:4502) Capex-to-Revenue : 0.06 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Takeda Pharmaceutical Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Takeda Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2024 was 円-64,326.00 Mil. Its Revenue for the three months ended in Mar. 2024 was 円1,050,869.00 Mil.

Hence, Takeda Pharmaceutical Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.06.


Takeda Pharmaceutical Co Capex-to-Revenue Historical Data

The historical data trend for Takeda Pharmaceutical Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Capex-to-Revenue Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.07 0.05 0.16 0.11

Takeda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.25 0.07 0.07 0.06

Competitive Comparison of Takeda Pharmaceutical Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Capex-to-Revenue falls into.



Takeda Pharmaceutical Co Capex-to-Revenue Calculation

Takeda Pharmaceutical Co's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-480730) / 4263762
=0.11

Takeda Pharmaceutical Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-64326) / 1050869
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co  (SSE:4502) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Takeda Pharmaceutical Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (SSE:4502) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (SSE:4502) Headlines

No Headlines